Johnson & Johnson Announces Opening of Boston Innovation Center

       Johnson & Johnson Announces Opening of Boston Innovation Center

First Collaborations Announced Between Regional Innovators and Johnson &
Johnson Family of Companies

PR Newswire

CAMBRIDGE, Mass., June 27, 2013

CAMBRIDGE, Mass., June 27, 2013 /PRNewswire/ --Johnson & Johnson today
announced the opening of the Johnson & Johnson Innovation center in Boston,
the third of four regional hubs being established in the world's leading life
science hotspots. A part of Johnson & Johnson Innovation, the goal of the
Boston Innovation Center is to advance healthcare by catalyzing collaborations
in science and technology between regional innovators and the Johnson &
Johnson Family of Companies across a diverse spectrum of early-stage
opportunities.

The Boston Innovation Center is home to a team of business, science and
transaction experts who are focused on identifying and building novel
early-stage collaborations with emerging companies, entrepreneurs and academic
centers across eastern North America. This team has full and broad deal-making
capabilities, with flexibility to adapt deal structures to match early-stage
needs and opportunities.

"The East Coast's significance as a hotbed for life sciences innovation
grounded in collaboration is indisputable, and continues to grow," said Paul
Stoffels, M.D., Johnson & Johnson Chief Scientific Officer and Worldwide
Chairman, Pharmaceuticals. "With the establishment of our Boston Innovation
Center, we look forward to further fostering collaboration with some of the
world's leading scientists, renowned academic centers, and influential
entrepreneurs to enable future innovations that will advance human health."


Representatives of Johnson & Johnson Development Corporation (JJDC), the
venture capital subsidiary of Johnson & Johnson, are co-located at the Boston
Innovation Center to identify and invest in external opportunities. Since its
inception in 1973, JJDC has been among the top-tier healthcare venture capital
companies investing in and developing new businesses that create leading
technologies, products and services.

"In Massachusetts we invest in the life sciences because we are choosing to
shape our own future," said Governor Deval Patrick. "I welcome the Johnson &
Johnson Innovation center to our life sciences supercluster and look forward
to the jobs and economic opportunities that their new collaborations will
bring."

Johnson & Johnson Innovation today announced the Boston Innovation Center's
first collaborations and new initiatives, including new relationships with
leading academic researchers and emerging biotech companies, as well as
funding to support the needs of the next generation of startup life science
ventures. New collaborations and initiatives include:

Research Alliance with Mount Sinai – Janssen Biotech, Inc. and Johnson &
Johnson Innovation have established a research alliance with The Icahn School
of Medicine at Mount Sinai to advance the scientific understanding of
inflammatory bowel disease (IBD) and the discovery of next generation
therapeutic solutions.Scientists from the Janssen Immunology Therapeutic Area
and researchers from Mount Sinai will work in partnership to investigate
disease triggers, identify new opportunities for therapeutic interventions and
establish diagnostics to facilitate precision medicine and predictive
biomarkers. The first-of-its-kind industry and academic partnership brings
together Janssen research and development capabilities with an early-stage
life science investment through the Johnson & Johnson Innovation center in
Boston and Mount Sinai's expertise in computational biology, clinical and
translational research in IBD.

Collaboration with Rodin Therapeutics – Johnson & Johnson Development
Corporation (JJDC) has made an investment in Rodin Therapeutics, a
biotechnology company focused on applying insights of epigenetics to advance
novel therapeutics for neurological disorders such as Alzheimer's disease. The
Boston Innovation Center and Janssen Research & Development, LLC, part of the
Janssen Pharmaceutical Companies of Johnson & Johnson, will engage in
scientific collaboration with Rodin Therapeutics with the goal of sharing
knowledge and expertise to advance novel solutions in CNS.

Investment in Vedanta Biosciences – JJDC has made an investment in Vedanta
Biosciences to facilitate the Boston Innovation Center collaboration with
Vedanta to advance a novel class of therapies that modulate pathways of
interaction between the human microbiome and the host immune system. Vedanta
has developed a discovery platform to mine novel mechanisms by which the
microbiome modulates the immune system, and is working to advance a
first-in-class preclinical candidate for autoimmune and inflammatory diseases
such as Inflammatory Bowel Disease (IBD). The Janssen Pharmaceutical Companies
of Johnson & Johnson have identified the human microbiome as a strategic area
of research and seek to forge collaborations with leading companies with
promising programs in this emerging field of science. Vedanta was co-founded
by PureTech Ventures and a group of world-renowned experts in immunology and
microbiology.

Expanded Janssen Labs to Cambridge, Mass. –Johnson & Johnson Innovation will
establish Janssen Labs at the LabCentral facility in the Kendall Square
biotech hub. Janssen Labs @LabCentral marks the first East Coast expansion for
Janssen Labs, which will operate with the same open-innovation,
no-strings-attached approach as it does at the flagship Janssen Labs in San
Diego and the recently announced Janssen Labs @QB3 with University of
California, San Francisco. As a Founding Sponsor of LabCentral, Johnson &
Johnson Innovation will select a few high-potential innovators for the
shared-laboratory space who are focused on promising science that addresses
important unmet medical needs. LabCentral is a nonprofit organization,
designed to be a "one-stop-shop," offering premier, fully equipped laboratory
space, plus the infrastructure and support that emerging life sciences
companies need to transition from a science/technology-focus to a successful
commercial-stage enterprise. As part of this agreement, Johnson & Johnson
Innovation will also have an on-site office to facilitate collaboration with
other start-ups located at LabCentral. 

"We are thrilled to officially open the doors to the Boston Innovation Center
today, deepening our long-held commitment to supporting this vibrant life
science ecosystem," said Robert Urban, Ph.D., Head, Boston Innovation
Center."We look forward to serving as a single point of entry for innovators
to efficiently and creatively explore relationships and investment
opportunities across the Johnson & Johnson Family of Companies, with the
ultimate goal of bringing new innovations to improve health and patient care."

The Boston Innovation Center augments the existing presence and contributions
of the Johnson & Johnson Family of Companies in the state, which includes
headquarters in Raynham, Mass., for the DePuy Family of Companies, global
leaders in providing healthcare solutions in orthopaedics, spinal care, sports
medicine and neurosciences.

In addition to the new Johnson & Johnson Innovation center in Boston, a center
in London opened in March, a center in California opened in early June, and a
fourth is planned to open in Shanghai by the end of the year. Each city was
selected for its robust life sciences community, which provides a rich
environment for identifying investment, in-licensing and collaboration
opportunities.

The Boston Innovation Center is located at One Cambridge Center, Cambridge,
Massachusetts, 02142. For more information on the new innovation centers
please contact jnjinnovation@its.jnj.com.

About Johnson & Johnson
Caring for the world, one person at a time…inspires and unites the people of
Johnson & Johnson. We embrace research and science – bringing innovative
ideas, products and services to advance the health and well-being of people.
Our approximately 128,000 employees at more than 275 Johnson & Johnson
operating companies work with partners in health care to touch the lives of
over a billion people every day throughout the world.

For more information, visit www.jnj.com.

About Johnson & Johnson Innovation
The Boston Innovation Center is part of Johnson & Johnson Innovation, a
division of Johnson & Johnson Finance Corporation. Johnson & Johnson
Innovation focuses on accelerating early innovation and enhancing
opportunities for collaboration and investment across Johnson & Johnson's
global healthcare businesses. Johnson & Johnson Innovation provides
scientists, entrepreneurs and emerging companies focused on early-stage
opportunities a one-stop access to science and technology experts who can
facilitate collaborations across the pharmaceutical, medical device and
diagnostics and consumer companies of Johnson & Johnson. Johnson & Johnson
Innovation includes local deal-making capabilities with the flexibility to
adapt deal structures to match early-stage opportunities and establish novel
collaborations that speed development of those innovations to solve unmet
needs in patients. Follow us @jnjinnovation on Twitter. More information can
be found here: www.jnjinnovation.com.

Forward-looking Statements
This press release contains "forward-looking statements" as defined in the
Private Securities Litigation Reform Act of 1995. The reader is cautioned not
to rely on these forward-looking statements. These statements are based on
current expectations of future events. If underlying assumptions prove
inaccurate or unknown risks or uncertainties materialize, actual results could
vary materially from the expectations and projections of the Johnson & Johnson
Finance Corporation, any of the Janssen Pharmaceutical Companies and/or
Johnson & Johnson. Risks and uncertainties include, but are not limited to,
general industry conditions and competition; economic factors, such as
interest rate and currency exchange rate fluctuations; technological advances,
new products and patents attained by competitors; challenges inherent in new
product development, including obtaining regulatory approvals; challenges to
patents; impact of business combinations; changes in behavior and spending
patterns or financial distress of purchasers of health care products and
services; changes to governmental laws and regulations and domestic and
foreign health care reforms; trends toward health care cost containment; and
increased scrutiny of the health care industry by government agencies. A
further list and description of these risks, uncertainties and other factors
can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K
for the fiscal year ended December 30, 2012. Copies of this Form 10-K, as well
as subsequent filings, are available online at www.sec.gov, www.jnj.com or on
request from Johnson & Johnson. Johnson & Johnson Finance Corporation, the
Janssen Pharmaceutical Companies and Johnson & Johnson do not undertake to
update any forward-looking statements as a result of new information or future
events or developments.

Media Contact:  Investors:
Seema Kumar   Stan Panasewicz
908-405-1144  732-524-2524
skumar10@its.jnj.com
Meghan Marschall Louise Mehrotra
201-323-0578    732-524-6491
mmarscha@its.jnj.com

SOURCE Johnson & Johnson

Website: http://www.jnj.com
 
Press spacebar to pause and continue. Press esc to stop.